SYNTHON HISPANIA SL
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Medicinal Chemicals and Botanical Products), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about SYNTHON HISPANIA SL
Live alerts from global media, monitored by Business Radar
2024-01-19 (thehindubusinessline.com)
Zydus Lifesciences subsidiary signs licensing agreement with Synthon BV
Zydus Worldwide DMCC partners with Synthon BV to manufacture and market Palbociclib tablets in the US.
Read more
2017-10-05 (prnewswire.com)
Mylan, in Partnership with Synthon, Receives Marketing Authorization Approval in Europe for First Generic for Copaxone® 40 mg/mL
/PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that partner, Synthon, received marketing authorization approval in Europe for Glatiramer...
Read more
2012-07-18 (pwnet.nl)
License agreement between Synthon and Amgen & Watson
The Dutch pharmaceutical company Synthon has entered into a licensing agreement with Amgen and Watson regarding the drug trastuzumab. The Dutch company reports this in a news item. Synthon is developing trastuzumab as a 'biosimilar' of the drug Herceptin, a monoclonal
Read more
(prnewswire.com)
leica biosystems and synthon biopharmaceuticals partner to develop a companion diagnostic program for targeted cancer therapies
/PRNewswire/ -- Leica Biosystems and Synthon Biopharmaceuticals announce partnership to develop a companion diagnostic test for solid tumors Leica Biosystems...
Read more